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ABSTRACT
The incidence of hetero-intermediate glycopep-
tide susceptibility among Staphylococcus aureus
isolates in Malta, a country with a high incidence
of methicillin resistance, was studied by screening
454 non-repetitive S. aureus isolates on teicopla-
nin-supplemented agar plates, followed by Etests
and genotypic studies. All strains were suscept-
ible to vancomycin, but four (0.88%) exhibited
teicoplanin MICs of > 12 mg ⁄L. High methicillin-
resistant S. aureus endemicity was not an accurate
predictor of the emergence of non-susceptibility
to glycopeptides.
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Strains of Staphylococcus aureus with reduced
susceptibility to the glycopeptides vancomycin
and teicoplanin were ﬁrst reported from Japan in
1997 [1]. Further reports from Japan have indi-
cated that these strains of S. aureus, with vanco-
mycin MICs of < 4 mg ⁄L, may include resistant
sub-population variants, occurring at a frequency
of approximately 1 · 10)6 [2]. The clinical signi-
ﬁcance of these hetero-resistant isolates remains
a matter of considerable debate and it is not
recommended to report them as glycopeptide-
intermediate S. aureus (GISA) in clinical laborat-
ory reports [3]. Nevertheless, strains of glyco-
peptide hetero-intermediate S. aureus (hGISA)
have been associated with therapeutic failure [4].
It has also been postulated that hGISA strains
may be precursors for the development of the
GISA phenotype [2]. Therefore, their quantiﬁca-
tion may offer an insight into the possibility of
emergence of GISA in a particular geographical
location [5].
Malta is an island country in the Mediterra-
nean with a population of 400 000, and is
considered to have a high endemicity of meth-
icillin-resistant S. aureus (MRSA), with > 45% of
S. aureus isolates from blood cultures being
reported as methicillin-resistant. No clinical cases
of GISA have ever been reported. Consecutive
non-repetitive S. aureus isolates (n = 454) were
examined over a 9-month period between Janu-
ary and September 2003 at the Microbiology
Laboratory of St Luke’s Hospital, the only
tertiary-care hospital on the island. Glycopeptide
susceptibility testing followed the technical pro-
cedure recommended by the European Antimi-
crobial Resistance Surveillance System [6], based
on the study of Walsh et al. [7] and the method
of screening for GISA adopted by the French
Microbiology Society [8]. Screening was under-
taken by growing the bacteria overnight in
brain–heart infusion broth (Oxoid, Basingstoke,
UK); 10 lL of the stationary-phase culture was
then inoculated on to a Mueller–Hinton agar
(Oxoid) plate containing teicoplanin 5 mg ⁄L. The
plates were incubated for 48 h at 37 ± 0.5C.
Growth of two or more colonies was deemed to
be a positive result, whereupon the colonies
were analysed further by the Etest method.
The inoculum for Etests was prepared in brain–
heart infusion broth (BBL, Cockeysville, MD,
USA) to a density of 2· McFarland standards.
Aliquots of 200 lL were spread evenly with a
swab on two 90-mm brain–heart infusion agar
(Oxoid) plates. The plates were then left to stand
to allow the inoculum to soak into the plate, after
which Etest strips for teicoplanin and vancomycin
were applied according to the manufacturer’s
instructions (AB Biodisk, Solna, Sweden). The
plates were read after 48 h at 37 ± 0.5C, with
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particular attention paid to any ‘micro’ colonies or
small colony variants growing in the Etest ellipse.
If colonies were found growing at cut-off levels of
‡ 12 mg ⁄L for the teicoplanin plate, or ‡ 8 mg ⁄L
for both the teicoplanin and vancomycin plates
[7], the isolates were then analysed by pulsed-
ﬁeld gel electrophoresis typing and 16S)23S
rRNA intergenic spacer polymorphism analysis
[9,10].
Of the 454 isolates tested, 14 (3.1%) yielded an
average of 24 CFU ⁄plate (range: 2–100 CFU ⁄
plate) on the glycopeptide screening plate. Vanco-
mycin MICs for these 14 isolates were
1.5–4 mg ⁄L; however, only four (0.88%) isolates
were deﬁned as glycopeptide non-susceptible on
the basis of a teicoplanin MIC of > 12 mg ⁄L. Two
isolates had been submitted from within St Luke’s
Hospital itself (renal and intensive care units),
while the other two originated from a geriatric
rehabilitation hospital and a district general hos-
pital, respectively (Table 1). All four of these
isolates were non-susceptible to methicillin and
penicillin. This is not surprising, as resistance to
glycopeptides in S. aureus is found predominantly
among MRSA isolates [11]. The isolate designated
Malta-3 was also resistant to cefuroxime, eryth-
romycin and ciproﬂoxacin. The three other iso-
lates had wider antimicrobial resistance proﬁles,
including resistance to lincomycins and amino-
glycosides.
The four isolates were grouped into three
clusters by pulsed-ﬁeld gel electrophoresis.
Malta-3 was a clonal variant (four bands differ-
ence) of the most prevalent community MRSA
clone (MLST type 80) in Europe, and carried the
PVL toxin gene associated with this clone
(results not shown) [12]. The two variants (one
band difference) of the Malta-1 clone were
similar to one of the major international epi-
demic MRSA clonal complexes (CC5) by pulsed-
ﬁeld gel electrophoresis and 16S)23S rRNA
intergenic spacer polymorphism analysis. The
ﬁrst Japanese GISA isolate and ﬁve of the USA
GISA isolates also belonged to this clonal
complex [13].
Malta is among the countries with the highest
incidence of MRSA in Europe [6]. Studies in other
Mediterranean countries with high MRSA levels
have reported varying GISA and h-GISA rates,
ranging from 65% in Spain [14] to 1.1% in Italy
[11] and 0.6% in France [15]. The rate of 0.88%
identiﬁed in Malta supports the hypothesis that
the mere prevalence of methicillin resistance in a
particular geographical area is not an accurate
predictor of the likelihood of glycopeptide non-
susceptibility.
The results of the present study differed from
those reported in other Mediterranean countries,
in that all teicoplanin hetero-intermediate strains
isolated in Malta were susceptible to vancomycin.
Exposure to glycopeptides is recognised as a risk
factor for the emergence of resistance in S. aureus
[16]. Teicoplanin is the most popular glycopeptide
used in Malta, with annual deﬁned daily doses
more than ﬁve-fold greater than those for vanco-
mycin. Further studies are needed to establish
whether the predominant use of teicoplanin in
a setting with a high MRSA prevalence and
substantial glycopeptide consumption has any
impact on reducing the emergence of vancomycin
resistance in S. aureus.
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ABSTRACT
A prospective study of throat cultures and max-
illary sinus aspirates from children with chronic
sinusitis (n = 21), acute sinusitis (n = 28) or a
clinical diagnosis of chronic adenoiditis (n = 41)
was performed. Seventy-two bacterial pathogens
were isolated from sinus aspirates from 52% of
the study population. Haemophilus inﬂuenzae was
most common pathogen, followed by Moraxella
catarrhalis, Streptococcus pneumoniae, Staphylococcus
aureus, and group A streptococci. Quantitative
throat cultures had positive predictive values of
41%, 53% and 75% for H. inﬂuenzae, Strep.
pneumoniae and M. catarrhalis, respectively, while
negative predictive values were 93–98%, indica-
ting that these three pathogens do not cause
sinusitis when absent from the throat.
Keywords Children, Haemophilus inﬂuenzae, Moraxella
catarrhalis, sinusitis, Streptococcus pneumoniae, throat
cultures
Original Submission: 9 May 2004; Revised Submis-
sion: 13 December 2004; Accepted: 23 December 2004
Clin Microbiol Infect 2005; 11: 407–410
10.1111/j.1469-0691.2005.01132.x
Sinusitis is a common complication of upper
respiratory tract virus infection and allergic inﬂam-
mation [1]. Sinus cavity aspiration is the most
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